Literature DB >> 26690378

Antitoxin Treatment of Inhalation Anthrax: A Systematic Review.

Eileen Huang, Satish K Pillai, William A Bower, Katherine A Hendricks, Julie T Guarnizo, Jamechia D Hoyle, Susan E Gorman, Anne E Boyer, Conrad P Quinn, Dana Meaney-Delman.   

Abstract

Concern about use of anthrax as a bioweapon prompted development of novel anthrax antitoxins for treatment. Clinical guidelines for the treatment of anthrax recommend antitoxin therapy in combination with intravenous antimicrobials; however, a large-scale or mass anthrax incident may exceed antitoxin availability and create a need for judicious antitoxin use. We conducted a systematic review of antitoxin treatment of inhalation anthrax in humans and experimental animals to inform antitoxin recommendations during a large-scale or mass anthrax incident. A comprehensive search of 11 databases and the FDA website was conducted to identify relevant animal studies and human reports: 28 animal studies and 3 human cases were identified. Antitoxin monotherapy at or shortly after symptom onset demonstrates increased survival compared to no treatment in animals. With early treatment, survival did not differ between antimicrobial monotherapy and antimicrobial-antitoxin therapy in nonhuman primates and rabbits. With delayed treatment, antitoxin-antimicrobial treatment increased rabbit survival. Among human cases, addition of antitoxin to combination antimicrobial treatment was associated with survival in 2 of the 3 cases treated. Despite the paucity of human data, limited animal data suggest that adjunctive antitoxin therapy may improve survival. Delayed treatment studies suggest improved survival with combined antitoxin-antimicrobial therapy, although a survival difference compared with antimicrobial therapy alone was not demonstrated statistically. In a mass anthrax incident with limited antitoxin supplies, antitoxin treatment of individuals who have not demonstrated a clinical benefit from antimicrobials, or those who present with more severe illness, may be warranted. Additional pathophysiology studies are needed, and a point-of-care assay correlating toxin levels with clinical status may provide important information to guide antitoxin use during a large-scale anthrax incident.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26690378      PMCID: PMC4710135          DOI: 10.1089/hs.2015.0032

Source DB:  PubMed          Journal:  Health Secur        ISSN: 2326-5094


  46 in total

1.  Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax.

Authors:  Bethany Biron; Katie Beck; David Dyer; Marc Mattix; Nancy Twenhafel; Aysegul Nalca
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

2.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  J Clin Epidemiol       Date:  2009-07-23       Impact factor: 6.437

Review 3.  Anthrax cases in pregnant and postpartum women: a systematic review.

Authors:  Dana Meaney-Delman; Marianne E Zotti; Sonja A Rasmussen; Sheryl Strasser; Sean Shadomy; Reina M Turcios-Ruiz; George D Wendel; Tracee A Treadwell; Denise J Jamieson
Journal:  Obstet Gynecol       Date:  2012-12       Impact factor: 7.661

Review 4.  Pathology of inhalational anthrax animal models.

Authors:  N A Twenhafel
Journal:  Vet Pathol       Date:  2010-07-23       Impact factor: 2.221

Review 5.  Systematic review: a century of inhalational anthrax cases from 1900 to 2005.

Authors:  Jon-Erik C Holty; Dena M Bravata; Hau Liu; Richard A Olshen; Kathryn M McDonald; Douglas K Owens
Journal:  Ann Intern Med       Date:  2006-02-21       Impact factor: 25.391

Review 6.  Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.

Authors:  Anette Schneemann; Marianne Manchester
Journal:  Future Microbiol       Date:  2009-02       Impact factor: 3.165

Review 7.  Raxibacumab.

Authors:  Sohini Mazumdar
Journal:  MAbs       Date:  2009-11-29       Impact factor: 5.857

8.  Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax.

Authors:  Nutan Mytle; Robert J Hopkins; Nina V Malkevich; Subhendu Basu; Gabriel T Meister; Daniel C Sanford; Jason E Comer; Kristopher E Van Zandt; Mohamed Al-Ibrahim; William G Kramer; Cris Howard; Nancy Daczkowski; Ajoy C Chakrabarti; Boris Ionin; Gary S Nabors; Mario H Skiadopoulos
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

9.  Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States.

Authors:  J A Jernigan; D S Stephens; D A Ashford; C Omenaca; M S Topiel; M Galbraith; M Tapper; T L Fisk; S Zaki; T Popovic; R F Meyer; C P Quinn; S A Harper; S K Fridkin; J J Sejvar; C W Shepard; M McConnell; J Guarner; W J Shieh; J M Malecki; J L Gerberding; J M Hughes; B A Perkins
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

10.  Lethal factor and anti-protective antigen IgG levels associated with inhalation anthrax, Minnesota, USA.

Authors:  Mark D Sprenkle; Jayne Griffith; William Marinelli; Anne E Boyer; Conrad P Quinn; Nicki T Pesik; Alex Hoffmaster; Joseph Keenan; Billie A Juni; David D Blaney
Journal:  Emerg Infect Dis       Date:  2014-02       Impact factor: 6.883

View more
  19 in total

Review 1.  Neuroterrorism Preparedness for the Neurohospitalist.

Authors:  Maj Samuel A Ralston; Maj Brian P Murray; Daniel Vela-Duarte; Karen D Orjuela; Daniel M Pastula
Journal:  Neurohospitalist       Date:  2018-10-21

2.  Self-defense against Bacillus anthracis toxins: Is P-selectin the key?

Authors:  John D Campbell
Journal:  Virulence       Date:  2017-03-10       Impact factor: 5.882

3.  Bacillus anthracis edema toxin inhibits hypoxic pulmonary vasoconstriction via edema factor and cAMP-mediated mechanisms in isolated perfused rat lungs.

Authors:  Xizhong Cui; Jeffrey Wang; Yan Li; Zoe G Couse; Thomas F Risoleo; Mahtab Moayeri; Stephen H Leppla; Daniela Malide; Zu-Xi Yu; Peter Q Eichacker
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-10-16       Impact factor: 4.733

4.  Passive protection against anthrax in mice with plasma derived from horses hyper-immunized against Bacillus anthracis Sterne strain.

Authors:  Marc Caldwell; Terri Hathcock; Kenny V Brock
Journal:  PeerJ       Date:  2017-12-15       Impact factor: 2.984

Review 5.  A systematic review and meta-analysis of preclinical trials testing anti-toxin therapies for B. anthracis infection: A need for more robust study designs and results.

Authors:  Wanying Xu; Lernik Ohanjanian; Junfeng Sun; Xizhong Cui; Dante Suffredini; Yan Li; Judith Welsh; Peter Q Eichacker
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

6.  Characterisation of the antibacterial properties of the recombinant phage endolysins AP50-31 and LysB4 as potent bactericidal agents against Bacillus anthracis.

Authors:  Sangjin Park; Soo Youn Jun; Chang-Hwan Kim; Gi Mo Jung; Jee Soo Son; Seong Tae Jeong; Seong Jun Yoon; Sang Yup Lee; Sang Hyeon Kang
Journal:  Sci Rep       Date:  2018-01-08       Impact factor: 4.379

Review 7.  Sharpening Host Defenses during Infection: Proteases Cut to the Chase.

Authors:  Natalie C Marshall; B Brett Finlay; Christopher M Overall
Journal:  Mol Cell Proteomics       Date:  2017-02-08       Impact factor: 5.911

8.  Anthrax immune globulin improves hemodynamics and survival during B. anthracis toxin-induced shock in canines receiving titrated fluid and vasopressor support.

Authors:  Dante A Suffredini; Xizhong Cui; Dharmvir Jaswal; Kenneth E Remy; Yan Li; Junfeng Sun; Steven B Solomon; Yvonne Fitz; Mahtab Moayeri; Stephen Leppla; Peter Q Eichacker
Journal:  Intensive Care Med Exp       Date:  2017-10-23

9.  Estimation of Time Period for Effective Human Inhalational Anthrax Treatment Including Antitoxin Therapy.

Authors:  Lewis Rubinson; Alfred Corey; Dan Hanfling
Journal:  PLoS Curr       Date:  2017-07-28

10.  Establishment of a New Zealand White Rabbit Model for Lethal Toxin (LT) Challenge and Efficacy of Monoclonal Antibody 5E11 in the LT-Challenged Rabbit Model.

Authors:  Duanyang Zhang; Weicen Liu; Zhonghua Wen; Bing Li; Shuling Liu; Jianmin Li; Wei Chen
Journal:  Toxins (Basel)       Date:  2018-07-12       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.